Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-1827452 in Heart Failure and Systolic Dysfunction
NCT00748579Phase 2Terminated
- Sponsor
- Cytokinetics
- Start
- Sep 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of omecamtiv mecarbil in heart failure (HF) and left ventricular systolic dysfunction (LVSD), sponsored by Cytokinetics. Started Sep 2008; status: terminated.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NCT00748579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748579.